AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
August 18, 2021 07:05 ET | AzurRx BioPharma, Inc.
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
August 17, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares
July 27, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
July 22, 2021 16:51 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
June 08, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
May 19, 2021 07:30 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
May 13, 2021 07:00 ET | AzurRx BioPharma, Inc.
Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
May 11, 2021 08:30 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)
May 11, 2021 07:30 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...